Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors.

Recurrence of high-risk bladder cancer: a population-based analysis. Cancer (2013) 1.87

Quality of care in patients with bladder cancer: a case report? Cancer (2011) 1.73

Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer (2011) 1.55

Recent advances in the diagnosis and treatment of bladder cancer. BMC Med (2013) 1.20

Contemporary management of low-risk bladder cancer. Nat Rev Urol (2011) 0.93

Surveillance and treatment of non-muscle-invasive bladder cancer in the USA. Adv Urol (2012) 0.86

Bladder cancer: Low adherence to guidelines in non-muscle-invasive disease. Nat Rev Urol (2016) 0.76

Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know? Bladder Cancer (2015) 0.75

The Role of Population-Based Observational Research in Bladder Cancer. Bladder Cancer (2015) 0.75

Clinical Practice Pattern of Immediate Intravesical Chemotherapy following Transurethral Resection of a Bladder Tumor in Korea: National Health Insurance Database Study. Sci Rep (2016) 0.75

When medical evidence alone is simply not enough. Cancer (2009) 0.75

Words of wisdom. Re: treatment of non-muscle invading bladder cancer: do physicians in the United States practice evidence based medicine? Eur Urol (2010) 0.75

Health services research in urology. World J Urol (2011) 0.75

Cancer statistics, 2006. CA Cancer J Clin (2006) 30.71

Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care (2005) 7.73

Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol (2000) 4.28

Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol (2002) 4.08

A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol (2004) 3.75

Identification of individuals with CKD from Medicare claims data: a validation study. Am J Kidney Dis (2005) 2.65

Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol (1999) 2.03

Guidelines on bladder cancer. Eur Urol (2002) 1.97

Long-term outcome of hematuria home screening for bladder cancer in men. Cancer (2006) 1.95

An approach to identifying incident breast cancer cases using Medicare claims data. J Clin Epidemiol (2000) 1.83

Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care (2003) 1.75

United States radiation oncologists' and urologists' opinions about screening and treatment of prostate cancer vary by region. Urology (2002) 1.73

Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. J Urol (2006) 1.64

The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol (1996) 1.63

Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br J Urol (1997) 1.62

Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol (1999) 1.47

Gender, racial and age differences in bladder cancer incidence and mortality. Urol Oncol (2004) 1.41

A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol (1993) 1.38

Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am (1992) 1.33

Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J Urol (1991) 1.21

Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. J Clin Oncol (1988) 1.11

Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. J Urol (1983) 1.10

Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup. J Urol (1992) 1.09

Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients. World J Urol (1997) 1.06

Long-term outcome of home dipstick testing for hematuria. World J Urol (2007) 1.03

The economic burden of anemia in cancer patients receiving chemotherapy. Value Health (2005) 1.00

Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol (1989) 1.00

Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. Urol Oncol (2011) 1.00

Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma. Br J Urol (1976) 1.00

Intravesical therapy for superficial bladder cancer: slow but steady progress. J Clin Oncol (2003) 0.87

Intravesical therapy. A critical review. Urol Clin North Am (1987) 0.87

Transurethral resection with perioperative instilation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study--Finnbladder III. J Urol (1999) 0.86

An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy. Urol Clin North Am (2000) 0.86

Bladder cancer: twenty years of progress and the challenges that remain. CA Cancer J Clin (1998) 0.85

The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. Urology (1996) 0.84

Local BCG failures in superficial bladder cancer. A multivariate analysis of risk factors influencing survival. Eur Urol (1991) 0.81

A phase II study of prophylactic intravesical chemotherapy with 4'-epirubicin in recurrent superficial bladder cancer: comparison of 4'-epirubicin and adriamycin. Cancer Chemother Pharmacol (1994) 0.80

Management of bladder cancer. J Urol (2004) 0.80

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol (2006) 11.26

Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2011) 7.24

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer (2006) 5.03

Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med (2008) 4.71

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70

Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2012) 4.42

Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood (2008) 4.06

Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol (2007) 4.06

American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol (2013) 4.03

Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer (2006) 3.86

Association between stroke center hospitalization for acute ischemic stroke and mortality. JAMA (2011) 3.68

Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer (2011) 3.54

Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int (2010) 3.47

Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.S. employers. J Occup Environ Med (2004) 3.43

131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med (2005) 3.38

Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer (2007) 3.27

Retracted Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA (2008) 3.26

Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer (2004) 3.15

Human embryonic stem cell lines generated without embryo destruction. Cell Stem Cell (2008) 3.11

Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer (2009) 3.10

Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time. Cancer (2012) 2.98

Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol (2011) 2.76

NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw (2011) 2.73

Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer (2011) 2.67

Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst (2007) 2.59

Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci U S A (2008) 2.47

Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care (2005) 2.37

Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol (2004) 2.33

Adult genitourinary sarcoma: the 25-year Memorial Sloan-Kettering experience. J Urol (2006) 2.30

Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med (2005) 2.25

Prevalence and perceived health associated with insomnia based on DSM-IV-TR; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; and Research Diagnostic Criteria/International Classification of Sleep Disorders, Second Edition criteria: results from the America Insomnia Survey. Biol Psychiatry (2010) 2.22

Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer (2005) 2.20

Long-term outcome of patients with a negative work-up for asymptomatic microhematuria. Urology (2009) 2.18

Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. J Clin Oncol (2006) 2.17

Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol (2005) 2.13

The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion (2007) 2.12

Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol (2006) 2.03

Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol (2012) 2.02

Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate (2004) 1.96

Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol (2007) 1.92

Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol (2012) 1.85

Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med (2008) 1.85

Insomnia and the performance of US workers: results from the America insomnia survey. Sleep (2011) 1.77

American Society of Clinical Oncology clinical practice guidelines: opportunities and challenges. J Clin Oncol (2008) 1.75

Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol (2003) 1.73

Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. J Biol Chem (2001) 1.69

Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res (2010) 1.66

Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw (2008) 1.65

Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther (2010) 1.64

Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder. Cancer (2011) 1.62

Activation of Ras/Erk pathway by a novel MET-interacting protein RanBPM. J Biol Chem (2002) 1.62

VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1alpha. EMBO Rep (2005) 1.57

Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor. Biochem Biophys Res Commun (2002) 1.56

Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. Ann Surg Oncol (2012) 1.56

A randomized controlled trial of intravesical bacillus calmette-guerin for treatment refractory interstitial cystitis. J Urol (2005) 1.54

A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer (2007) 1.54

High Rate of Positive Circumferential Resection Margins Following Rectal Cancer Surgery: A Call to Action. Ann Surg (2015) 1.53

Cost-effectiveness of the School-Based Asthma Therapy (SBAT) program. Pediatrics (2013) 1.52

Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin. BJU Int (2008) 1.48

Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int (2012) 1.46

Complications associated with extraperitoneal robot-assisted radical prostatectomy using the standardized Martin classification. Urology (2013) 1.44

Human cytomegalovirus interleukin-10 downregulates metalloproteinase activity and impairs endothelial cell migration and placental cytotrophoblast invasiveness in vitro. J Virol (2004) 1.43

The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa. Ann Pharmacother (2009) 1.42

Gender, racial and age differences in bladder cancer incidence and mortality. Urol Oncol (2004) 1.41

Identifying additional lymph nodes in radical cystectomy lymphadenectomy specimens. Mod Pathol (2011) 1.41

Bladder tumor markers. J Urol (2006) 1.40

Large Variation in Blood Transfusion Use After Colorectal Resection: A Call to Action. Dis Colon Rectum (2016) 1.40

Variation in the cost of medications for the treatment of colorectal cancer. Am J Manag Care (2008) 1.39

Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genet Med (2012) 1.39

Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol (2005) 1.38

Near infrared fluorescence imaging with robotic assisted laparoscopic partial nephrectomy: initial clinical experience for renal cortical tumors. J Urol (2011) 1.35

Longitudinal effect of intimate partner abuse on high-risk behavior among adolescents. Arch Pediatr Adolesc Med (2003) 1.31

Quantitative characterization of viscoelastic properties of human prostate correlated with histology. Ultrasound Med Biol (2008) 1.30

Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. J Clin Oncol (2008) 1.27

Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure. Ann Intern Med (2014) 1.27

Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II substudy. J Cardiovasc Electrophysiol (2007) 1.26

Microsomal prostaglandin E synthase-1 is overexpressed in inflammatory bowel disease. Evidence for involvement of the transcription factor Egr-1. J Biol Chem (2004) 1.26

Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat (2006) 1.25

The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity. EMBO J (2003) 1.24

Undertreatment of cancer patients with chemotherapy is a global concern. J Oncol Pract (2008) 1.23

Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 1.23

Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol (2009) 1.21

Human cytomegalovirus transmission from the uterus to the placenta correlates with the presence of pathogenic bacteria and maternal immunity. J Virol (2003) 1.21

Androgen deprivation therapy for prostate cancer. Expert Opin Pharmacother (2008) 1.19

Transmission of human cytomegalovirus from infected uterine microvascular endothelial cells to differentiating/invasive placental cytotrophoblasts. Virology (2002) 1.19

Nighttime insomnia symptoms and perceived health in the America Insomnia Survey (AIS). Sleep (2011) 1.19

Testicular microlithiasis: a review and its association with testicular cancer. Urol Oncol (2004) 1.18

Dalbavancin or oritavancin for skin infections. N Engl J Med (2014) 1.16

Viral and bacterial pathogens at the maternal-fetal interface. J Infect Dis (2004) 1.16

Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer (2004) 1.16

Robot-assisted and laparoscopic partial nephrectomy with near infrared fluorescence imaging. J Endourol (2012) 1.15

Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health (2008) 1.14

Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. Proc Natl Acad Sci U S A (2002) 1.14